Search Results

You are looking at 1 - 10 of 566 items for :

Clear All
Full access

Rahul Aggarwal, Tian Zhang, Eric J. Small and Andrew J. Armstrong

and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma

Full access

Peter R. Carroll and Andrew J. Vickers

“Screening for prostate cancer has been a public health disaster,” announced Andrew J. Vickers, PhD, Attending Research Methodologist, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City. At the

Full access

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead and Maria Ho

Prostate cancer has surpassed lung cancer as the most common cancer in men. Experts generally accept that these changes resulted from prostate-specific antigen (PSA) screening that detected many early-stage prostate cancers. An estimated 233,000 new cases

Full access

Douglass B. Clayton and Donald A. Urban

. Attitude and self-reported practice regarding prognostication in a national sample of internists . Arch Intern Med 1998 ; 258 : 2389 – 2395 . 4. The American Urologic Association Prostate Cancer Clinical Guidelines Panel . The management of

Full access

Yoshio Naya and Koji Okihara

. CA Cancer J Clin 2003 ; 53 : 5 – 26 . 2 Catalona WJ Smith DS Ratliff TL . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer . N Engl J Med 1991 ; 324 : 1156 – 1161 . 3 Babaian RJ

Full access

Amit D. Raval, Suresh Madhavan, Malcolm D. Mattes, Mohamad Salkini and Usha Sambamoorthi

quality of care for non–cancer-related conditions. For example, among elderly men (age ≥66 years) with localized prostate cancer, the quality of care for acute chronic conditions is neglected. 3 Furthermore, among men of all ages with prostate cancer

Full access

Badar M. Mian

. CA Cancer J Clin 2003 ; 53 : 5 – 26 . 2 Hodge KK McNeal JE Terris MK .: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate . J Urol 1989 ; 142 : 71 – 74 . 3 Stamey TA . Making the

Full access

Brandon R. Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard J. Lee and Joseph E. Ippolito

Role of Multiparametric MRI in Diagnosis Conventional screening for prostate cancer (PCa) consists of digital rectal examination (DRE) and serum prostate-specific antigen (PSA) testing, followed by transrectal ultrasound (TRUS)–guided prostate

Full access

Christopher J. Magnani, Kevin Li, Tina Seto, Kathryn M. McDonald, Douglas W. Blayney, James D. Brooks and Tina Hernandez-Boussard

Background Prostate cancer is the most common cancer in US men; in 2019, 174,700 new cases are estimated, accounting for 20% of all new cancers in men, with 31,700 deaths. 1 However, a lack of consensus remains regarding best practices for

Full access

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski and Patrick C. Walsh

Prostate Cancer Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus